Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids

Shahead Ali Chowdhury1, Kaori Kishino, Rie Satoh

  • 1Meikai Pharmaco-Medical Laboratory (MPL), Meikai University School of Dentistry, Sakado, Saitama, Japan.

Anticancer Research
|September 15, 2005
PubMed

Insights

Eleven stilbenes and flavonoids show promising tumor-specific cytotoxicity. Sophorastilbene A and quercetin exhibit significant anti-cancer activity, inducing apoptosis in cancer cells while sparing normal cells.

Area of Science:

  • Natural Products Chemistry
  • Pharmacology
  • Cancer Biology

Background:

  • Stilbenes and flavonoids are natural compounds with potential therapeutic applications.
  • Investigating their anti-cancer properties is crucial for developing new treatments.

Purpose of the Study:

  • To evaluate the tumor-specific cytotoxicity and apoptosis-inducing activity of eleven stilbenes and flavonoids.
  • To compare the effects of these compounds on various human tumor and normal oral cell lines.

Main Methods:

  • Cytotoxicity assays were performed on four human tumor cell lines (HSC-2, HSC-3, HSG, HL-60) and three normal human oral cell lines (HGF, HPC, HPLF).
  • Apoptosis induction was assessed by measuring DNA fragmentation and caspase activation (caspases -3, -8, -9) in sensitive cell lines.
  • Western blot analysis was used to examine the expression of key apoptosis-related proteins (Bax, Bad, Bcl-2).

Main Results:

  • Several compounds, notably sophorastilbene A, (+)-alpha-viniferin, piceatannol, quercetin, and isoliquiritigenin, demonstrated higher cytotoxicity against tumor cells than normal cells.
  • The HSC-2 and HL-60 cell lines were most sensitive to the cytotoxic effects.
  • Sophorastilbene A, piceatannol, quercetin, and isoliquiritigenin induced DNA fragmentation and caspase activation in HL-60 cells, indicating apoptosis induction.

Conclusions:

  • Selected stilbenes and flavonoids exhibit significant tumor-specific cytotoxicity and apoptosis-inducing potential.
  • The compounds' efficacy varies depending on the cell line, with HSC-2 and HL-60 being particularly sensitive.
  • Further research into these compounds could lead to novel anti-cancer therapeutics.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...